Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
IMASMART
1 other identifier
interventional
90
1 country
1
Brief Summary
This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable alzheimer-disease
Started Jul 2023
Typical duration for not_applicable alzheimer-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 24, 2023
CompletedFirst Posted
Study publicly available on registry
February 2, 2023
CompletedStudy Start
First participant enrolled
July 20, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 20, 2026
March 11, 2026
March 1, 2026
3.3 years
January 24, 2023
March 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of a mathematical combination
The comparison of a mathematical combination of the different parameters collected during the three months of smartphone data recording
Up to three months
Study Arms (3)
Memory complaint
OTHERMild cognitive decline
OTHERAlzheimer's Disease
OTHERInterventions
Recording of smartphone usage data
Eligibility Criteria
You may qualify if:
- Patient consulting in routine care in one of the CMRR
- No sensory impairment that may compromise smartphone use
You may not qualify if:
- Inability to perform MMSE or MMSE \< 20 ;
- Other neurodegenerative condition (Parkinson's disease, Lewy body disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis)
- Severe anxiety or depressive disorder HADS score ≥ 17
- Terminal phase of a severe disease
- Evidence of a lesion on MRI that may be involved in cognitive impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Poitiers University Hospitallead
- University of Poitierscollaborator
Study Sites (1)
CHU Poitiers
Poitiers, 86000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2023
First Posted
February 2, 2023
Study Start
July 20, 2023
Primary Completion (Estimated)
October 20, 2026
Study Completion (Estimated)
October 20, 2026
Last Updated
March 11, 2026
Record last verified: 2026-03